Spurs announce jersey deal with Paris-based digital asset security firm Ledger
Ledger is based in Paris, where the Spurs played two games last season. The Spurs have long had an enormous following in France, with players like Tony Parker and Boris Diaw playing for San Antonio before the team drafted Wembanyama in 2023.
'This moment cements a decades-long history of international collaboration and growth by the Spurs organization, as the game of basketball has grown to touch every culture and continent,' said RC Buford, the CEO of Spurs Sports & Entertainment.
It is a multi-year deal, but specific terms were not announced.
Ledger is a relatively new company. It was started 10 years ago to help safeguard digital assets for cryptocurrency users. It has grown wildly since, now used by millions of individuals around the world to secure more than 20% of all crypto.
'Aligning ourselves with an historic U.S. sports team, which boasts a deep French connection past and present, will help us onboard the next generation of sovereign individuals," said Pascal Gauthier, Chairman & CEO of Ledger. 'The San Antonio Spurs, at the heart of America in Texas, is the future of the league, growing their fandom rapidly, and the most international team the NBA has to offer."
The Spurs have had players from more than 30 countries play for the organization.
They will debut their new Ledger-branded jerseys at the NBA draft on Wednesday. They currently have the No. 2 and No. 14 picks in the first round. The first game with the new patch will be at the California Classic summer league on July 5, and the patches will be on both the San Antonio and the G League's Austin Spurs jerseys.
Also in the deal: Ledger will join the Spurs' ongoing community efforts in Paris, which started earlier this year with the team launching a multi-year plan to renovate outdoor basketball courts. Ledger also becomes the presenting partner of Spurs Tech & Basketball Camp, which uses sports and technology applications to engage school-aged participants ages 10-14 — connecting young basketball players with science, technology, engineering, and math and showing how all those elements are tied to the game.
___
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the article L. 233-8 II of the French 'Code de Commerce' and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or ' AMF ') General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (' Innate ' or the ' Company ') releases its total number of shares outstanding as well as its voting rights as of July 3, 2025: (1) The total number of theoretical voting rights (or 'gross' voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017. (2) The total number of exercisable voting rights (or 'net' voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (A ntibody-based NK cell E ngager T herapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate's portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at and follow us on LinkedIn and X. Information about Innate Pharma shares Disclaimer on forward-looking information and risk factors This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'may,' 'might,' 'potential,' 'intend,' 'should,' 'will,' or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
Yahoo
6 hours ago
- Yahoo
‘Real recognize real' says Ledger exec on surprise sports deal
'Real recognize real' says Ledger exec on surprise sports deal originally appeared on TheStreet. Ian Rogers, chief experience officer at Ledger, unpacked the company's decision to back the San Antonio Spurs with a multi-year jersey-patch sponsorship. 'Real recognize real,' Rogers said in an interview with TheStreet Roundtable, invoking his hip-hop roots to explain the choice. Rogers emphasized that Ledger and the Spurs share core values of hard work, integrity and a global outlook. 'The Spurs are a unique ball club — their ethics match ours,' he said. He pointed to the franchise's international legacy, from Tony Parker's Hall of Fame career to Victor Wembanyama's rising star power, as a mirror to Ledger's own footprint. 'We ship our product into 200 countries every month,' Rogers noted — an advantage over region-locked FinTech firms constrained by local regulation. By aligning with an NBA team that transcends U.S. markets, Rogers believes Ledger can better communicate its mission of financial empowerment. 'In America, we want to talk to people about financial freedom and the next phase of owning their financial journey,' he stablecoins and crypto assets become embedded across websites, Rogers warned of heightened fraud risks. 'You might have significant value in stored-value accounts and stablecoins across many sites on the internet soon,' he said. That proliferation of dispersed balances, he argued, underscores the importance of hardware wallets and two-factor authentication. Whether as a second factor for services like Coinbase and Robinhood or as a standalone vault, Ledger's tools protect users from phishing and hacks. Beyond sports marketing, Rogers highlighted recent Ledger initiatives. The company rolled out its Recovery Key feature this spring and launched the CL credit card in the U.S., enabling users to spend crypto anywhere credit cards are accepted and earn Bitcoin as cash-back rewards. 'We're always building new hardware, integrating blockchains and adding services,' Rogers said. He described Ledger's guiding principle as delivering 'the most secure hardware with the best user experience — no compromise on security or self-custody.' Rogers concluded by reaffirming the partnership's dual purpose: to work hard and play hard, while educating a new generation of trendsetters. 'It's the most fun I've ever had in my career,' he said. 'We're here to push the envelope on financial empowerment.' 'Real recognize real' says Ledger exec on surprise sports deal first appeared on TheStreet on Jul 3, 2025 This story was originally reported by TheStreet on Jul 3, 2025, where it first appeared.
Yahoo
6 hours ago
- Yahoo
Report: Spurs told to pay £65m after fresh transfer bid fails
Tottenham's Kudus Pursuit Hits a Wall as West Ham Stand Firm Spurs Up the Ante for Kudus Tottenham Hotspur are not giving up on their pursuit of Mohammed Kudus, with TBR Football reporting that the North London club have returned with a second bid after seeing their initial £50 million offer rejected by West Ham United. Advertisement According to the report, Spurs have now proposed a package worth £55 million (£50m guaranteed plus £5m in add-ons), only to see that too knocked back. West Ham, who signed Kudus from Ajax for £38 million two years ago, are holding out for a fee that 'must at least start with a six.' West Ham Standing Their Ground TBR Football's update highlights the Hammers' firm position. 'West Ham United decided to reject the latest offer and are standing firm over their asking price, adamant that any accepted offer must at least start with a six,' reads the report. The East London club are reportedly demanding around £65 million for Kudus – a figure they view as 'quite reasonable' given his £84 million release clause. It's also worth noting that Kudus is reportedly 'open' to making the switch across the capital, as per Fabrizio Romano. Photo: IMAGO Advertisement Despite West Ham's willingness to sell for the right price to fund their own transfer business, they are clearly not entertaining cut-price deals. Spurs Running Out of Forward Options? Tottenham have shifted focus to Kudus after cooling interest in Crystal Palace's Eberechi Eze and walking away from a potential £70 million outlay for Bournemouth's Antoine Semenyo. David Ornstein previously revealed Spurs baulked at that fee, which might suggest Kudus could soon fall into the same bracket of unaffordability. With their club-record transfer fee sitting at £65 million for Dominic Solanke last summer, it appears Spurs are unwilling to surpass that threshold unless they believe the deal is justifiable from a long-term value perspective. Advertisement What Next for Tottenham? It remains to be seen whether Spurs will submit a third bid closer to West Ham's valuation or if they'll once again pivot to other targets. The North London side clearly see Kudus as a player capable of taking the team forward – his blend of athleticism, technical ability and versatility is well suited to Thomas Frank's system. But with West Ham unwilling to compromise and Kudus under a long-term contract, Tottenham may be forced to either meet the demands or walk away. Our View – EPL Index Analysis There's a real mix of admiration and frustration among Spurs fans reading this update. On one hand, Mohammed Kudus is exactly the kind of player that fits the project under Frank – explosive, versatile, and still only 24. His performances for West Ham were electric at times, and fans recognise his ceiling is far from reached. Advertisement But there's also a sense that this could be another classic Tottenham story – showing strong interest, making offers that fall short, and eventually watching a talent go elsewhere. If Spurs walked away from Antoine Semenyo at £70m, and are now hesitating over a £65m-rated Kudus, it begs the question: what is the plan? Supporters appreciate not overspending, especially given the financial landscape and FFP pressures, but there's growing concern that the club is unwilling to go that extra mile to secure top targets. And with Kudus reportedly open to the move, this might be the best time to strike. The longer this drags, the more likely other suitors – potentially with deeper pockets – could enter the race. There's also an understanding that West Ham are not being entirely unreasonable. Kudus has a high release clause, he's on a long-term contract, and he's one of their best assets. If Spurs are serious, £65m isn't outlandish in today's market. The ball is firmly in Daniel Levy's court.
